[1]杜国庆,潘富伟,王玉鹏,等.强骨胶囊治疗原发性骨质疏松症有效性和安全性的Meta分析[J].中医正骨,2023,35(08):31-36.
　DU Guoqing,PAN Fuwei,WANG Yupeng,et al.Clinical outcomes and safety of Qianggu(强骨)capsules for treatment of primary osteoporosis:a meta-analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(08):31-36.
点击复制

强骨胶囊治疗原发性骨质疏松症有效性和安全性的Meta分析()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第35卷
期数:
2023年08期
页码:
31-36
栏目:
文献研究
出版日期:
2023-08-20

文章信息/Info

Title:
Clinical outcomes and safety of Qianggu(强骨)capsules for treatment of primary osteoporosis:a meta-analysis
作者:
杜国庆1; 潘富伟1; 王玉鹏1; 石金玉1; 李正言1; 廉由之2; 陆洁航1; 章振林3; 詹红生1
1.上海中医药大学附属曙光医院,上海 201203; 2.上海市宝山区中西医结合医院,上海 201999; 3.上海交通大学附属第六人民医院,上海 200233
Author(s):
DU Guoqing1; PAN Fuwei1; WANG Yupeng1; SHI Jinyu1; LI Zhengyan1; LIAN Youzhi2; LU Jiehang1; ZHANG Zhenlin3; ZHAN Hongsheng1
1.Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China2.Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai 201999,China3.The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China
关键词:
骨质疏松; 强骨胶囊; 专题Meta分析; 有效性; 安全性
Keywords:
osteoporosis;  Qianggu capsule;  meta-analysis as topic;  efficacy;  safety
摘要:
目的:系统评价强骨胶囊治疗原发性骨质疏松症(primary osteoporosis,POP)的有效性和安全性。方法:应用计算机检索中国生物医学文献服务系统、万方数据库、中国知网、维普网、PubMed、Medline、Cochrane Library、Embase,筛选强骨胶囊治疗POP的随机对照试验,试验组采用强骨胶囊或强骨胶囊联合常规疗法治疗,对照组采用常规疗法治疗。采用Cochrane偏倚风险评估工具对纳入研究的文献进行质量评估,采用RevMan5.3软件进行Meta分析。结果:共检索到1434篇文献,通过逐层筛选最终纳入9篇文献,均为中文文献。Meta分析结果显示,2组腰椎骨密度、临床有效率、不良反应发生率比较,差异均无统计学意义[SMD=0.25,95%CI(-0.15,0.65),P=0.210; RR=1.10,95%CI(0.96,1.26),P=0.160; OR=1.53,95%CI(0.82,2.85),P=0.180],试验组股骨颈骨密度高于对照组[SMD=0.44,95%CI(0.16,0.71),P=0.002],骨痛积分低于对照组[MD=-1.00,95%CI(-1.50,-0.51),P=0.000]。结论:现有的证据表明,单独应用强骨胶囊或在常规疗法基础上联合应用强骨胶囊治疗POP,与单独应用常规疗法相比,在改善腰椎骨密度、临床综合疗效和安全性方面作用相当,但前者在缓解骨痛、改善股骨颈骨密度方面优于后者。
Abstract:
Objective:To systematically review the clinical outcomes and safety of Qianggu(强骨,QG)capsules in treatment of primary osteoporosis(POP).Methods:All the randomized controlled trial(RCT)articles about QG capsules for treatment of POP included from database establishing to September 30,2022 were retrieved from Chinese Biomedical Literature Service System,Wanfang Database,China National Knowledge Internet,Vip Database,PubMed,Medline,Cochrane Library and Embase through computer.The patients in experimental group were treated with oral application of QG capsules or combination of oral application of QG capsules with conventional therapies,while the ones in control group with conventional therapies alone.The methodological quality of researches in the articles was evaluated by using Cochrane bias risk assessment tools,and then a Meta-analysis was conducted by using RevMan5.3 software.Results:One thousand four hundred and thirty-four articles were searched out.After screening,9 Chinese articles(803 patients)were included in the final analysis,443 patients in experimental group and 360 ones in control group.The results of Meta-analysis revealed that there was no statistical difference in bone mineral density(BMD)of lumbar vertebrae,clinical efficacy rate and incidence rate of adverse reactions between the 2 groups(SMD=0.25,95%CI(-0.15,0.65),P=0.210; RR=1.10,95%CI(0.96,1.26),P=0.160; OR=1.53,95%CI(0.82,2.85),P=0.180),while the BMD of femoral neck was higher,the bone pain score was lower in experimental group compared to control group(SMD=0.44,95%CI(0.16,0.71),P=0.002; MD=-1.00,95%CI(-1.50,-0.51),P=0.000).Conclusion:Available evidences suggest that oral application of QG capsules alone or combination of oral application of QG capsules with conventional therapy is similar to conventional therapy alone in improving BMD of lumbar vertebrae,total clinical curative effects and safety in treatment of POP,however,the former is better than the latter in relieving bone pain and improving BMD of femoral neck.

参考文献/References:

[1] 中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):317-318.
[2] 中华医学会骨科学分会骨质疏松学组.骨质疏松性骨折诊疗指南[J].中华骨科杂志,2017,37(1):1-10.
[3] 中华医学会骨质疏松与骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志,2019,25(3):281-309.
[4] 李梅,章振林,夏维波.骨质疏松症药物治疗的必由之路:长程序贯治疗[J].中华骨质疏松和骨矿盐疾病杂志,2021,14(5):441-446.
[5] 中国中西医结合学会骨伤科专业委员会.骨质疏松症中西医结合诊疗指南[J].中华医学杂志,2019,99(45):3524-3533.
[6] 黄委委,李哲,郑旭耀,等.中成药治疗原发性骨质疏松症疗效的系统评价[J].中国骨质疏松杂志,2019,25(12):1798-1808.
[7] 《中成药治疗优势病种临床应用指南》标准化项目组.中成药治疗骨质疏松症临床应用指南(2021)[J].中国中西医结合杂志,2022,42(4):393-404.
[8] 彭红玲.强骨胶囊联合唑来膦酸治疗绝经后骨质疏松症临床研究[J].中西医结合研究,2023,15(2):73-76.
[9] 赵光,徐则李,邵琼星,等.利维爱及中药补肾法防治绝经后妇女骨质疏松症的临床对比研究[J].中国骨质疏松杂志,2004,10(3):337-339.
[10] 徐宏,任德华,梁柱,等.强骨胶囊合阿仑磷酸钠治疗绝经后骨质疏松症的临床研究[J].浙江中医药大学学报,2010,34(4):503-504.
[11] 王健,张维康,王朝晖.强骨胶囊治疗绝经后骨质疏松症28例[J].医药导报,2007,26(11):1325-1327.
[12] 阮祥燕,齐久梅,刘玉兰,等.中药对绝经妇女股骨颈骨密度及股骨颈抗骨折能力的影响[J].中国骨质疏松杂志,2006,12(2):181-184.
[13] 万明,王康振,高大伟,等.鲑鱼降钙素联合强骨胶囊对原发性骨质疏松症患者骨代谢的影响[J].中国药业,2018,27(15):61-63.
[14] 谢雁鸣,崔天红,高蕊,等.强骨胶囊治疗原发性骨质疏松症(肾阳虚证)的临床研究[J].中药新药与临床药理,2000,11(4):197-201.
[15] 单硕,周光.强骨胶囊治疗原发性骨质疏松症的临床疗效[J].西北药学杂志,2006,21(4):177-178.
[16] 谢雁鸣,王和鸣,沈霖,等.强骨胶囊治疗原发性骨质疏松症162例多中心随机对照临床研究[J].中医杂志,2004,45(7):506-509.
[17] 夏文芳,陈璐璐.强骨胶囊与利塞膦酸钠治疗绝经后骨质疏松症的对比研究[J].中国骨质疏松杂志,2006,12(4):393-396.
[18] 夏维波,CYRUS COOPER,李梅,等.东方遇见西方:增龄性骨骼肌肉疾病的临床实践和策略[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(5):432-455.
[19] 徐道明,许华宁,徐帅,等.原发性骨质疏松症慢性疼痛的康复治疗进展[J].中国骨质疏松杂志,2020,26(8):1197-1200.
[20] 何椋,李凤珍,张志勇,等.中成药治疗原发性骨质疏松症系统评价的再评价[J].湖南中医杂志,2022,38(7):110-114.
[21] 中华医学会骨质疏松与骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):7.
[3]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):12.
[4]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[5]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):27.
[6]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):19.
[7]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):20.
[8]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):5.
[9]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):21.
[10]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(08):16.

备注/Memo

备注/Memo:
基金项目:《中成药治疗优势病种临床应用指南》标准化项目第三批优势病种指南子课题(SATCM-2015-BZ402-042); 全国名老中医药专家传承工作室建设项目(国中医药人教函〔2022〕75号); 上海市2020年度“科技创新行动计划”医学创新研究专项项目(20MC1920600) 通讯作者:詹红生 E-mail:zhanhongsheng2010@163.com 章振林 E-mail:zhangzl@sjtu.edu.cn
更新日期/Last Update: 1900-01-01